Information Provided By: 
Fly News Breaks for February 24, 2020
HRTX, PCRX
Feb 24, 2020 | 07:11 EDT
H.C. Wainwright analyst Oren Livnat raised the firm's price target on Pacira Pharmaceuticals (PCRX) to $63 from $60 and keeps a Buy rating on the shares. The analyst "significantly" increased his earnings estimates to reflect the company's better leverage following its Q4 results. Getting past the likely competitor approval of Heron Therapeutics' (HRTX) HTX-011 "could finally bring in investors off of sidelines," Livnat tells investors in a research note.
News For PCRX;HRTX From the Last 2 Days
HRTX
Apr 26, 2024 | 10:52 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Heron Therapeutics (HRTX),... To see the rest of the story go to thefly.com. See Story Here
HRTX
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
